Abstract Objective To analyze the clinical efficacy of daily online cone-beam computed tomography (CBCT)-guided stereotactic body radiation therapy (SBRT) for primary and metastatic lung cancer and its related factors. Methods From May 2009 to May 2013, 36 patients with lung cancer were treated with SBRT, including 24 patients with primary lung cancer and 12 patients with metastatic lung cancer. The biologically effective dose at 10 Gy was ≥100 Gy in 85.7% of 42 lesions. Before each delivery, CBCT was acquired, and online automatic or manual registration was performed to make the tumors on CBCT within the planning target volume/primary gross tumor volume;the setup threshold was not set, and the couch was moved for correction. Results The 1-, 2-, and 3-year sample sizes were 36, 29, and 26, respectively. The 1-, 2-, and 3-year local control (LC) rates were 96%, 89%, and 72%, respectively. The 1-, 2-, and 3-year cancer-specific survival (CCS) rates were 82%, 74%, and 64%, respectively. The 1-, 2-, and 3-year overall survival (OS) rates were 78%, 64%, and 53%, respectively. Univariate analysis found no factors associated with LC. Multivariate analysis revealed no factors associated with OS. Both univariate and multivariate analyses showed that only tumor location (central type or peripheral type) was associated with CCS;the mean values (95% confidence intervals) of CCS in patients with central-type and peripheral-type lesions were 21.4 months (13.2—29.6 months) and 42.3 months (35.7—49.0 months), respectively (P=0.024). Conclusions Daily online image-guided SBRT for primary or metastatic lung cancer can lead to a satisfactory LC.
Gao Hong,Li Gaofeng,Zhong Qiuzi et al. Clinical efficacy of daily online image-guided stereotactic body radiation therapy for lung cancer[J]. Chinese Journal of Radiation Oncology, 2014, 23(4): 322-325.
Gao Hong,Li Gaofeng,Zhong Qiuzi et al. Clinical efficacy of daily online image-guided stereotactic body radiation therapy for lung cancer[J]. Chinese Journal of Radiation Oncology, 2014, 23(4): 322-325.
[1] Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. JAMA,2010,303:1070-1076. [2] Fakiris AJ, Mcgarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma:four-year results of a prospective phase Ⅱ study[J]. Int J Radiat Oncol Biol Phys,2009,75:677-682. [3] Hellman S, Weichselbaum RR. Oligometastases[J]. J Clin Oncol,1995,13:8-10. [4] Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for lung metastases[J]. J Clin Oncol,2009,27:1579-1584. [5] Hamamoto Y, Kataoka M, Yamashita M, et al. Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors[J]. Jpn J Radiol,2012,30:430-434. [6] van Baardwijk A, Tome WA, van Elmpt W, et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage Ⅰ non-small cell lung cancer (NSCLC) overkill? A systematic review[J]. Radiother Oncol,2012,105:145-149. [7] Grills IS, Hope AJ, Guckenberger M, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy[J]. J Thorac Oncol,2012,7:1382-1393. [8] Timmerman RD, Bizekis CS, Pass HI, et al. Local surgical, ablative, and radiation treatment of metastases[J]. CA Cancer J Clin,2009,59:145-170. [9] Trakul N, Chang CN, Harris J, et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors[J]. Int J Radiat Oncol Biol Phys,2012,84:231-237. [10] Takeda A, Kunieda E, Ohashi T, et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer[J]. Radiother Oncol,2011,101:255-259. [11] Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors:relevance of 4D dose calculation[J]. Int J Radiat Oncol Biol Phys,2009,74:47-54. [12] Brown JM, Diehn M, Loo BJ. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer[J]. Int J Radiat Oncol Biol Phys,2010,78:323-327. [13] Matsuo Y, Shibuya K, Nagata Y, et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2011,79:1104-1111. [14] Wulf J, Baier K, Mueller G, et al. Dose-response in stereotactic irradiation of lung tumors[J]. Radiother Oncol,2005,77:83-87. [15] Galerani AP, Grills I, Hugo G, et al. Dosimetric impact of online correction via cone-beam CT-based image guidance for stereotactic lung radiotherapy[J]. Int J Radiat Oncol Biol Phys,2010,78:1571-1578.
2014, Vol. 23 
